{"entity":{"id":"hla-typing-and-nomenclature","kind":"term","name":"HLA allele names and typing reports","aka":["HLA nomenclature","HLA genotyping","HLA allele name","HLA typing resolution"],"tldr":"HLA typing reads the inherited versions of the genes that display protein fragments. The name tells you how precisely the version is known, not whether a tumour still shows a given fragment.","summary":"In an allele name such as HLA-A*02:01:01:01 the fields carry distinct meanings (official HLA nomenclature). HLA-A is the gene; 02 is the allele group, which often corresponds to a serological antigen; the second field (01) distinguishes protein sequences within the group, since alleles differing there differ in at least one amino-acid-changing substitution; the third field distinguishes synonymous coding differences; the fourth distinguishes differences outside the coding region. An optional suffix gives expression status: N for a null allele, and L, S, C, A or Q for alternatively expressed alleles, L meaning significantly reduced surface expression. A name without a suffix is not a measurement of how much HLA a cancer cell expresses. A shared first field does not establish identical proteins, and a report stating only A*02 at group resolution cannot be silently completed as A*02:01.\n\nPeople generally inherit one copy of each HLA gene from each parent, so a report lists two alleles per locus, which can be the same name. Class I and class II typing describe different display molecules. Typing identifies inheritance; it does not show tumour retention or expression, peptide display or receptor recognition, and a negative display assay does not by itself show the typing was wrong. Loss of an allele in the tumour, or changes in antigen-processing machinery, can interrupt the chain after an accurate typing result. A trial may name an allele and an accepted method; eligibility belongs to the study team and neither a similar name nor correct typing shows targetability.\n\nLaboratory typing starts from an accepted specimen and extracted DNA, tests sequence patterns with primers or probes or reads selected regions by Sanger or next-generation sequencing, optionally after PCR amplification, and compares the result with a reference database (IPD-IMGT/HLA). Hosomichi et al. (2013) describe phase-defined sequencing of six HLA genes by long-range PCR and multiplex sequencing: phasing connects differences on the same inherited copy, and unresolved phase or a missing distinguishing region can leave alternative allele pairs despite good base quality. More reads of the same regions cannot settle such an ambiguity; the distinguishing information must be added, and both alternatives should be kept until it is. Software can infer class I HLA from genome, exome or RNA sequencing: Szolek et al. (2014) reported OptiType's overall accuracy of 97 per cent on their benchmark of RNA, exome and whole-genome data. Capture, coverage and expression affect such inference, and an inference is not automatically a laboratory result accepted for clinical use. Reports should be read with resolution, ambiguity notes, coverage, database version and validation.\n\nThe IPD-IMGT/HLA statistics page read on 9 November 2026 listed 46,146 HLA alleles, 31,311 of them class I and 14,835 class II, so exact allele names matter.","asOf":"2026-11-11","links":[{"label":"HLA nomenclature: naming alleles","url":"https://hla.alleles.org/pages/nomenclature/naming_alleles/"},{"label":"IPD-IMGT/HLA statistics page (read 9 November 2026)","url":"https://www.ebi.ac.uk/ipd/imgt/hla/about/statistics/"},{"label":"Hosomichi et al., 2013, BMC Genomics (PMID 23714642)","url":"https://doi.org/10.1186/1471-2164-14-355"},{"label":"Szolek et al., 2014, Bioinformatics (PMID 25143287)","url":"https://doi.org/10.1093/bioinformatics/btu548"}],"tags":["education-immunology-2026-11"],"related":["hla","hla-a-02-01","hla-a02-restriction","antigen-processing-machinery"],"cancers":[],"sections":[],"technologies":[],"targets":["hla-a","hla-b","hla-c"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["hla","hla-a02-restriction"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["The page does not print a release number, so the allele counts are dated by the day they were read rather than by release. The Guide cites release 3.66.","Existing record hla-a-02-01 covers HLA-A*02:01 as an eligibility marker for TCR therapies; this record covers how names and reports are read.","A fictional report lists HLA-A*02:01 and A*24:02, B*07:02 and B*08:01, and C*07:01 and C*07:02. These are two inherited copies at each of three loci; other people can share them. C*07:01 and C*07:02 name different protein variants despite their shared first field. A prediction for the first is not silently a prediction for the second. Likewise, strong predicted peptide-P binding to A*02:01 and a receptor response to P on A*24:02 do not establish one matched target. Source-protein RNA supplies a different observation. Match peptide, protein allele, model/version and response experiment, then test retention and natural display in the tumour.","In another fictional report, the observed differences permit two allele pairs because their arrangement between inherited copies remains unresolved. Choosing the pair with better peptide predictions does not resolve phase. Retain both alternatives and request evidence that connects the distinguishing positions on the same copy. Laboratory region coverage, reference version, resolution and ambiguity notes remain relevant even when base calls are high quality. A computational inference should retain its sequencing dataset, software/version and validation; neither a resolved research inference nor an accepted typing report is a peptide-display assay."],"category":"Immunology"},"route":"/terms/hla-typing-and-nomenclature/","neighbours":{"term":[{"id":"antigen-processing-machinery","kind":"term","name":"Antigen-processing machinery (APM)","route":"/terms/antigen-processing-machinery/"},{"id":"hla","kind":"term","name":"HLA (human leukocyte antigen) and MHC","route":"/terms/hla/"},{"id":"hla-a02-restriction","kind":"term","name":"HLA-A*02:01 restriction","route":"/terms/hla-a02-restriction/"},{"id":"neoantigen-candidate-selection","kind":"term","name":"Neoantigen candidate selection","route":"/terms/neoantigen-candidate-selection/"},{"id":"tumor-associated-antigen","kind":"term","name":"Tumour-associated antigen (TAA)","route":"/terms/tumor-associated-antigen/"}],"biomarker":[{"id":"hla-a-02-01","kind":"biomarker","name":"HLA-A*02:01 (HLA typing for TCR therapies)","route":"/biomarkers/hla-a-02-01/"}],"target":[{"id":"hla-a","kind":"target","name":"HLA-A","route":"/targets/hla-a/"},{"id":"hla-b","kind":"target","name":"HLA-B","route":"/targets/hla-b/"},{"id":"hla-c","kind":"target","name":"HLA-C","route":"/targets/hla-c/"}]}}